7 Nov 2020
Eisai Announces New Investigational Data Evaluating TKI-mTOR Inhibitor Regimen LENVIMA® (lenvatinib) Plus Everolimus in Advanced Renal Cell Carcinoma (RCC) at IKCS 2020
Author: admintech | Filed under: Press ReleaseWOODCLIFF LAKE, N.J., Nov. 7, 2020 /PRNewswire/ — Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor…